logo
Plus   Neg
Share
Email

Lanxess Q3 Profit Down; Realigns Organometallics Business - Quick Facts

Specialty chemicals company Lanxess AG (LNXSF.PK) reported that its third-quarter net income declined 13.8 percent to 69 million euros from last year's 80 million euros, mainly due to higher depreciation. Earnings per share decreased by 10.2 percent to 0.79 euros, due to the lower average number of shares outstanding after the share buyback program.

EBITDA pre exceptionals was 267 million euros, down 3.6 percent from the prior year. Earnings were negatively impacted in particular by lower demand from the automotive industry and the weak chrome ore business. However, this was almost offset by the company's stable portfolio and advantageous exchange-rate effects, especially from the strong U.S. dollar.

Group sales in the third quarter of 2019 were 1.78 billion euros on a par with the previous year's level.

The company expects its EBITDA pre exceptionals in the fourth quarter to be slightly better than in the previous year.

For the full year 2019, the company expects its EBITDA pre exceptionals to be between 1.000 billion euros and 1.050 billion euros, compared to 1.016 billion euros reported last year.

Lanxess said it is realigning its organometallics business in order to focus on profitable growth segments in the future. It is investing an amount in the mid-single-digit millions of euros at its location in Bergkamen, Germany, to expand production of aluminum-based organometallics, which are used as catalysts in the production of high-quality plastics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
RELATED NEWS
Follow RTT
>